WEC
ABBV icon

Winslow Evans & Crocker’s AbbVie ABBV Stock Holding History

Winslow Evans & Crocker’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$5.71M Buy
60,094
+16,051
+36% +$1.54M 1.08% 15
2020
Q3 		$3.86M Sell
44,043
-4,545
-9% -$428K 0.95% 18
2020
Q2 		$4.77M Buy
48,588
+5,598
+13% +$493K 1.27% 13
2020
Q1 		$3.28M Sell
42,990
-736
-2% -$62.7K 1.08% 15
2019
Q4 		$3.87M Buy
43,726
+1,218
+3% +$101K 0.99% 18
2019
Q3 		$3.22M Buy
42,508
+492
+1% +$33.7K 0.9% 20
2019
Q2 		$3.06M Sell
42,016
-1,946
-4% -$153K 0.85% 21
2019
Q1 		$3.55M Sell
43,962
-3,986
-8% -$326K 1.01% 18
2018
Q4 		$4.42M Buy
47,948
+2,276
+5% +$200K 1.49% 11
2018
Q3 		$4.32M Buy
45,672
+416
+0.9% +$39.5K 1.31% 13
2018
Q2 		$4.2M Buy
45,256
+1,150
+3% +$112K 1.32% 13
2018
Q1 		$4.17M Buy
44,106
+960
+2% +$105K 1.35% 14
2017
Q4 		$4.17M Sell
43,146
-844
-2% -$79.5K 1.34% 12
2017
Q3 		$3.91M Sell
43,990
-10,601
-19% -$807K 1.3% 12
2017
Q2 		$3.93M Buy
54,591
+4,765
+10% +$320K 1.08% 14
2017
Q1 		$3.25M Sell
49,826
-11,676
-19% -$734K 1.02% 17
2016
Q4 		$3.85M Sell
61,502
-3,092
-5% -$189K 1.18% 14
2016
Q3 		$4.07M Buy
64,594
+3,130
+5% +$203K 1.17% 14
2016
Q2 		$3.81M Sell
61,464
-1,445
-2% -$88K 1.14% 18
2016
Q1 		$3.59M Sell
62,909
-963
-2% -$53.7K 1.08% 19
2015
Q4 		$3.78M Buy
63,872
+4,852
+8% +$279K 1.08% 18
2015
Q3 		$3.21M Sell
59,020
-1,750
-3% -$114K 1.01% 22
2015
Q2 		$4.08M Buy
60,770
+1,064
+2% +$69.5K 1.15% 16
2015
Q1 		$3.5M Buy
59,706
+6,678
+13% +$403K 0.99% 21
2014
Q4 		$3.47M Buy
53,028
+582
+1% +$36.7K 0.99% 20
2014
Q3 		$3.03M Buy
52,446
+1,741
+3% +$96.7K 0.87% 20
2014
Q2 		$2.86M Buy
50,705
+945
+2% +$49.6K 0.95% 20
2014
Q1 		$2.56M Sell
49,760
-2,981
-6% -$151K 0.88% 25
2013
Q4 		$2.79M Buy
+52,741
New +$2.59M 0.95% 19

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Winslow Evans & Crocker's ABBV Position: Q4 2020 in Review

Winslow Evans & Crocker increased its AbbVie (ABBV) stake by 36% in Q4 2020, buying an estimated $1.54M and bringing the position to 60,094 shares worth $5.71M. The position accounts for 1.08% of the portfolio, ranked #15.

Winslow Evans & Crocker first reported a position in ABBV in Q4 2013 and has held it in 29 quarters since. 2,597 funds tracked by Wall St. Rank hold ABBV as of Q4 2020.

  • Winslow Evans & Crocker held 60,094 shares of AbbVie worth $5.71M as of Q4 2020.
  • Winslow Evans & Crocker bought 16,051 AbbVie shares in Q4 2020, an estimated $1.54M.
  • AbbVie made up 1.08% of Winslow Evans & Crocker's portfolio in Q4 2020, its #15 holding.
  • Winslow Evans & Crocker first reported a position in AbbVie in Q4 2013 and has held it in 29 quarters since.
  • 2,597 funds tracked by Wall St. Rank held AbbVie as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.